| 0.77 0.015 (1.96%) | 07-31 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.2 | 1-year : | 1.44 |
| Resists | First : | 1.03 | Second : | 1.24 |
| Pivot price | 1.01 |
|||
| Supports | First : | 0.7 | Second : | 0.58 |
| MAs | MA(5) : | 0.82 |
MA(20) : | 1.01 |
| MA(100) : | 2.95 |
MA(250) : | 7.61 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 8.2  |
D(3) : | 6.5 |
| RSI | RSI(14): 25.7 |
|||
| 52-week | High : | 31.73 | Low : | 0.7 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ARTL ] has closed above bottom band by 9.4%. Bollinger Bands are 77.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 42 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.82 - 0.83 | 0.83 - 0.83 |
| Low: | 0.75 - 0.75 | 0.75 - 0.76 |
| Close: | 0.76 - 0.77 | 0.77 - 0.78 |
Artelo Biosciences, Inc. functions as a clinical-stage biopharmaceutical enterprise dedicated to discovering and advancing therapies that modulate the endocannabinoid system. The company's robust developmental portfolio encompasses several promising candidates: ART27.13, a synthetic G protein-coupled receptor agonist currently undergoing Phase 1b/2a clinical investigation for cancer-related anorexia; ART12.11, a synthetic cannabidiol cocrystal being explored for inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor with potential applications in prostate and breast cancer treatment, as well as PTSD. Further extending its research efforts, Artelo has established a collaborative partnership with Trinity College Dublin to probe ART27.13's efficacy in addressing cancer cachexia. Established in 2011, the entity initially operated under the name Reactive Medical, Inc. before rebranding as Artelo Biosciences, Inc. in April 2017. Its corporate headquarters are situated in Solana Beach, California.
Tue, 28 Jul 2026
Price to earnings forward of Artelo Biosciences, Inc. – NASDAQ:ARTL - tradingview.com
Tue, 28 Jul 2026
Artelo Biosciences, Inc. Revenue Breakdown – NASDAQ:ARTL - tradingview.com
Sun, 26 Jul 2026
Artelo Biosciences Inc (ARTL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Tue, 21 Jul 2026
Artelo Biosciences grants options to director | ARTL Insider Trading - Stock Titan
Tue, 21 Jul 2026
Artelo Biosciences (ARTL) awards stock options to director Douglas Blayney - Stock Titan
Tue, 21 Jul 2026
Artelo Biosciences (NASDAQ: ARTL) awards 136-share option to director - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 3 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 2.4 (%) |
| Held by Institutions | 8.1 (%) |
| Shares Short | 169 (K) |
| Shares Short P.Month | 137 (K) |
| EPS | -29.02 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.61 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -91.4 % |
| Return on Equity (ttm) | -367.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -0.03 |
| PEG Ratio | 0 |
| Price to Book value | 0.1 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.34 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|